Companies › Beeline Medicines
1 active drug program in 2 registered trials: 2 Phase 2; Immunology; next expected readout Apr 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Afimetoran (BLN-256) Toll-like receptor 8 inhibitor; Toll-like receptor 7 inhibitor | TLR8, TLR7 | Phase 2 | Systemic Lupus Erythematosus; Cutaneous Lupus Erythematosus (CLE) | Apr 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04895696 | Afimetoran (BLN-256) | Phase 2 | Systemic Lupus Erythematosus | Immunology | Apr 2029 |
| NCT07881120 | Afimetoran (BLN-256) | Phase 2 | Cutaneous Lupus Erythematosus (CLE) | Immunology | Apr 2030 |
Calixis Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) Qifeng Zhang Topadur Pharma Leadingtac Pharmaceutical (Shaoxing)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.